Advertisement

A contemporary update on rates and management of toxicities of targeted therapies for metastatic renal cell carcinoma

Published:January 14, 2013DOI:https://doi.org/10.1016/j.ctrv.2012.12.006

      Abstract

      Background

      To provide an updated review of adverse events associated with sunitinib, pazopanib, bevacizumab, temsirolimus, axitinib, everolimus and sorafenib and their management.

      Materials and methods

      We performed a PubMed and Cochrane-based review of side effects associated with the seven agents including product monographs to provide an outline of treatment measures aiming to reduce their toxicities. Subject and outcome of interest, design type, sample size, pertinence and quality, and detail of reporting were the indicators of manuscript quality.

      Results

      All targeted therapies cause adverse events. Most adverse events may be prevented or tested before they escalate to severe levels.

      Conclusion

      Prevention, early recognition, and prompt management of side effects are of key importance and avoid unnecessary dose reductions, which may undermine treatment efficacy.

      Keywords

      To read this article in full you will need to make a payment
      ESMO Member Login
      Login with your ESMO username and password.
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Purchase one-time access:

      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Motzer R.J.
        • Hutson T.E.
        • Tomczak P.
        • et al.
        Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma.
        J Clin Oncol. 2009; 27: 3584
        • Motzer R.J.
        • Hutson T.E.
        • Tomczak P.
        • et al.
        Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.
        N Engl J Med. 2007; 356: 115
        • Sternberg C.N.
        • Davis I.D.
        • Mardiak J.
        • et al.
        Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial.
        J Clin Oncol. 2010; 28: 1061
        • Escudier B.
        • Bellmunt J.
        • Negrier S.
        • et al.
        Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival.
        J Clin Oncol. 2010; 28: 2144
        • Escudier B.
        • Pluzanska A.
        • Koralewski P.
        • et al.
        Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial.
        Lancet. 2007; 370: 2103
        • Rini B.I.
        • Halabi S.
        • Rosenberg J.E.
        • et al.
        Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206.
        J Clin Oncol. 2010; 28: 2137
        • Rini B.I.
        • Halabi S.
        • Rosenberg J.E.
        • et al.
        Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206.
        J Clin Oncol. 2008; 26: 5422
        • Hudes G.
        • Carducci M.
        • Tomczak P.
        • et al.
        Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma.
        N Engl J Med. 2007; 356: 2271
        • Rini B.I.
        • Escudier B.
        • Tomczak P.
        • et al.
        Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial.
        Lancet. 2011; 378: 1931
        • Motzer R.J.
        • Escudier B.
        • Oudard S.
        • et al.
        Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors.
        Cancer. 2010; 116: 4256
        • Motzer R.J.
        • Escudier B.
        • Oudard S.
        • et al.
        Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial.
        Lancet. 2008; 372: 449
        • Escudier B.
        • Eisen T.
        • Stadler W.M.
        • et al.
        Sorafenib in advanced clear-cell renal-cell carcinoma.
        N Engl J Med. 2007; 356: 125
        • Escudier B.
        • Eisen T.
        • Stadler W.M.
        • et al.
        Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial.
        J Clin Oncol. 2009; 27: 3312
        • Oxman A.D.
        • Guyatt G.H.
        Validation of an index of the quality of review articles.
        J Clin Epidemiol. 1991; 44: 1271
      1. Common Terminology Criteria for Adverse Events (CTCAE) and Common Toxicity Criteria (CTC): National Cancer Institute; 2006.

        • Gore M.E.
        • Szczylik C.
        • Porta C.
        • et al.
        Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial.
        Lancet Oncol. 2009; 10: 757
        • Tannir N.M.
        • Cohen L.
        • Wang X.
        • et al.
        Improved tolerability and quality of life with maintained efficacy using twice-daily low-dose interferon-alpha-2b: results of a randomized phase II trial of low-dose versus intermediate-dose interferon-alpha-2b in patients with metastatic renal cell carcinoma.
        Cancer. 2006; 107: 2254
        • Grunwald V.
        • Karakiewicz P.I.
        • Bavbek S.E.
        • et al.
        An international expanded-access programme of everolimus: addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy.
        Eur J Cancer. 2011; 48: 324
        • Beck J.
        • Procopio G.
        • Bajetta E.
        • et al.
        Final results of the European Advanced Renal Cell Carcinoma Sorafenib (EU-ARCCS) expanded-access study: a large open-label study in diverse community settings.
        Ann Oncol. 2011; 22: 1812
        • Stadler W.M.
        • Figlin R.A.
        • McDermott D.F.
        • et al.
        Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America.
        Cancer. 2010; 116: 1272
      2. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology. Cancer-Related Fatigue; 2012.

        • Morrow G.R.
        • Shelke A.R.
        • Roscoe J.A.
        • et al.
        Management of cancer-related fatigue.
        Cancer Invest. 2005; 23: 229
      3. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology. Palliative Care; 2012.

      4. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology. Myeloid Growth Factor; 2012.

        • Hutson T.E.
        • Davis I.D.
        • Machiels J.P.
        • et al.
        Efficacy and safety of pazopanib in patients with metastatic renal cell carcinoma.
        J Clin Oncol. 2010; 28: 475
        • Rini B.I.
        • Choueiri T.K.
        • Elson P.
        • et al.
        Sunitinib-induced macrocytosis in patients with metastatic renal cell carcinoma.
        Cancer. 2008; 113: 1309
        • Price J.
        • Shaarbaf R.
        • Wood L.
        Sunitinib causes macrocytosis in patients with advanced renal cell carcinoma.
        Curr Oncol. 2010; 17: 30
        • Schallier D.
        • Trullemans F.
        • Fontaine C.
        • et al.
        Tyrosine kinase inhibitor-induced macrocytosis.
        Anticancer Res. 2009; 29: 5225
      5. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology. Cancer- and Chemotherapy-Induced Anemia; 2012.

      6. Donskov, F, Carus, A, Barrios, CH, et al. Neutropenia and thromobocytopenia during treatment as biomarker of sunitinib efficacy in patients with metastatic renal cell carcinoma. In: ESMO meeting. Stockholm, 2011.

        • Hang X.F.
        • Xu W.S.
        • Wang J.X.
        • et al.
        Risk of high-grade bleeding in patients with cancer treated with bevacizumab: a meta-analysis of randomized controlled trials.
        Eur J Clin Pharmacol. 2011; 67: 613
        • Hidalgo M.
        • Buckner J.C.
        • Erlichman C.
        • et al.
        A phase I and pharmacokinetic study of temsirolimus (CCI-779) administered intravenously daily for 5 days every 2 weeks to patients with advanced cancer.
        Clin Cancer Res. 2006; 12: 5755
        • Je Y.
        • Schutz F.A.
        • Choueiri T.K.
        Risk of bleeding with vascular endothelial growth factor receptor tyrosine-kinase inhibitors sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials.
        Lancet Oncol. 2009; 10: 967
        • Rixe O.
        • Bukowski R.M.
        • Michaelson M.D.
        • et al.
        Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study.
        Lancet Oncol. 2007; 8: 975
        • Fakih M.G.
        • Lombardo J.C.
        Bevacizumab-induced nasal septum perforation.
        Oncologist. 2006; 11: 85
        • Ruiz N.
        • Fernandez-Martos C.
        • Romero I.
        • et al.
        Invasive fungal infection and nasal septum perforation with bevacizumab-based therapy in advanced colon cancer.
        J Clin Oncol. 2007; 25: 3376
        • Traina T.A.
        • Norton L.
        • Drucker K.
        • et al.
        Nasal septum perforation in a bevacizumab-treated patient with metastatic breast cancer.
        Oncologist. 2006; 11: 1070
        • Burkart C.M.
        • Grisel J.J.
        • Hom D.B.
        Spontaneous nasal septal perforation with antiangiogenic bevacizumab therapy.
        Laryngoscope. 2008; 118: 1539
        • Vandewiele B.
        • Vandecasteele S.J.
        • Vanwalleghem L.
        • et al.
        Diffuse alveolar hemorrhage induced by everolimus.
        Chest. 2010; 137: 456
        • Ranpura V.
        • Hapani S.
        • Chuang J.
        • et al.
        Risk of cardiac ischemia and arterial thromboembolic events with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis of randomized controlled trials.
        Acta Oncol. 2010; 49: 287
        • Hurwitz H.I.
        • Saltz L.B.
        • Van Cutsem E.
        • et al.
        Venous thromboembolic events with chemotherapy plus bevacizumab: a pooled analysis of patients in randomized phase II and III studies.
        J Clin Oncol. 2011; 29: 1757
        • Choueiri T.K.
        • Schutz F.A.
        • Je Y.
        • et al.
        Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials.
        J Clin Oncol. 2010; 28: 2280
      7. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology. Venous Thromboembolic Disease; 2012.

        • Benson 3rd, A.B.
        • Ajani J.A.
        • Catalano R.B.
        • et al.
        Recommended guidelines for the treatment of cancer treatment-induced diarrhea.
        J Clin Oncol. 2004; 22: 2918
      8. Gastrointestinal Complications. Health Professional version, National Cancer Institute at the National Institutes of Health; 2012.

        • Naskens D.
        • Mosher J.D.
        • O’Brien P.
        • et al.
        Living with kidney cancer-patient and family reference handbook.
        Pfizer Canada Inc., Kirkland, Quebec2009
      9. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology. Antiemesis; 2012.

        • Hapani S.
        • Chu D.
        • Wu S.
        Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis.
        Lancet Oncol. 2009; 10: 559
        • Fujisaka Y.
        • Yamada Y.
        • Yamamoto N.
        • et al.
        A Phase 1 clinical study of temsirolimus (CCI-779) in Japanese patients with advanced solid tumors.
        Jpn J Clin Oncol. 2010; 40: 732
        • Mackenzie M.J.
        • Rini B.I.
        • Elson P.
        • et al.
        Temsirolimus in VEGF-refractory metastatic renal cell carcinoma.
        Ann Oncol. 2011; 22: 145
        • Peters N.A.
        • Richel D.J.
        • Verhoeff J.J.
        • et al.
        Bowel perforation after radiotherapy in a patient receiving sorafenib.
        J Clin Oncol. 2008; 26: 2405
        • Rini B.I.
        • Wilding G.
        • Hudes G.
        • et al.
        Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma.
        J Clin Oncol. 2009; 27: 4462
        • Yoo C.
        • Kim J.E.
        • Lee J.L.
        • et al.
        The efficacy and safety of sunitinib in korean patients with advanced renal cell carcinoma: high incidence of toxicity leads to frequent dose reduction.
        Jpn J Clin Oncol. 2010; 40: 980
        • Loriot Y.
        • Boudou-Rouquette P.
        • Billemont B.
        • et al.
        Acute exacerbation of hemorrhagic rectocolitis during antiangiogenic therapy with sunitinib and sorafenib.
        Ann Oncol. 2008; 19: 1975
        • Flaig T.W.
        • Kim F.J.
        • La Rosa F.G.
        • et al.
        Colonic pneumatosis and intestinal perforations with sunitinib treatment for renal cell carcinoma.
        Invest New Drugs. 2009; 27: 83
        • Chow H.
        • Jung A.
        • Talbott J.
        • et al.
        Tumor fistulization associated with targeted therapy: computed tomographic findings and clinical consequences.
        J Comput Assist Tomogr. 2011; 35: 86
      10. Afinitor [package insert]. East Hanover (NJ): Novartis Pharmaceuticals.

      11. Torisel [package insert]. New York (NY): Pfizer.

      12. Votrient [package insert]. Philadelphia (PA): GlaxoSmithKline.

      13. Avastin [package insert]. South San Francisco (CA): Genentech.

      14. Nexavar [package insert]. Wayne (NJ): Bayer HealthCare Pharmaceuticals.

      15. Sutent [package insert]. New York (NY): Pfizer.

        • Gupta S.
        • Parsa V.
        • Heilbrun L.K.
        • et al.
        Safety and efficacy of molecularly targeted agents in patients with metastatic kidney cancer with renal dysfunction.
        Anticancer Drugs. 2011; 22: 794
        • Tortorici M.A.
        • Toh M.
        • Rahavendran S.V.
        • et al.
        Influence of mild and moderate hepatic impairment on axitinib pharmacokinetics.
        Invest New Drugs. 2011; 29: 1370
        • Mueller E.W.
        • Rockey M.L.
        • Rashkin M.C.
        Sunitinib-related fulminant hepatic failure: case report and review of the literature.
        Pharmacotherapy. 2008; 28: 1066
        • Weise A.M.
        • Liu C.Y.
        • Shields A.F.
        Fatal liver failure in a patient on acetaminophen treated with sunitinib malate and levothyroxine.
        Ann Pharmacother. 2009; 43: 761
        • Schramm C.
        • Schuch G.
        • Lohse A.W.
        Sorafenib-induced liver failure.
        Am J Gastroenterol. 2008; 103: 2162
        • Chobanian A.V.
        • Bakris G.L.
        • Black H.R.
        • et al.
        Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure.
        Hypertension. 2003; 42: 1206
      16. Arterial Hypertension (Management of): European Society of Cardiology Clinical Practice Guidelines, vol. 2007.

        • Wu S.
        • Chen J.J.
        • Kudelka A.
        • et al.
        Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis.
        Lancet Oncol. 2008; 9: 117
        • Zhu X.
        • Stergiopoulos K.
        • Wu S.
        Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: systematic review and meta-analysis.
        Acta Oncol. 2009; 48: 9
        • An M.M.
        • Zou Z.
        • Shen H.
        • et al.
        Incidence and risk of significantly raised blood pressure in cancer patients treated with bevacizumab: an updated meta-analysis.
        Eur J Clin Pharmacol. 2010; 66: 813
        • Rini B.I.
        • Cohen D.P.
        • Lu D.R.
        • et al.
        Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib.
        J Natl Cancer Inst. 2011; 103: 763
        • Bono P.
        • Rautiola J.
        • Utriainen T.
        • et al.
        Hypertension as predictor of sunitinib treatment outcome in metastatic renal cell carcinoma.
        Acta Oncol. 2011; 50: 569
        • Szmit S.
        • Langiewicz P.
        • Zlnierek J.
        • et al.
        Hypertension as a predictive factor for survival outcomes in patients with metastatic renal cell carcinoma treated with sunitinib after progression on cytokines.
        Kidney Blood Press Res. 2012; 35: 18
        • Rini B.I.
        • Schiller J.H.
        • Fruehauf J.P.
        • et al.
        Diastolic blood pressure as a biomarker of axitinib efficacy in solid tumors.
        Clin Cancer Res. 2011; 17: 3841
        • Bamias A.
        • Manios E.
        • Karadimou A.
        • et al.
        The use of 24-h ambulatory blood pressure monitoring (ABPM) during the first cycle of sunitinib improves the diagnostic accuracy and management of hypertension in patients with advanced renal cancer.
        Eur J Cancer. 2011; 47: 1660
        • Azizi M.
        • Chedid A.
        • Oudard S.
        Home blood-pressure monitoring in patients receiving sunitinib.
        N Engl J Med. 2008; 358: 95
        • Richards C.J.
        • Je Y.
        • Schutz F.A.
        • et al.
        Incidence and risk of congestive heart failure in patients with renal and nonrenal cell carcinoma treated with sunitinib.
        J Clin Oncol. 2011; 29: 3450
        • Tanigawa G.
        • Kawashima A.
        • Yamaguchi S.
        • et al.
        Clinical outcome and prognostic factors of sorafenib in Japanese patients with advanced renal cell carcinoma in general clinical practice.
        Jpn J Clin Oncol. 2011; 41: 1265
        • Uemura H.
        • Shinohara N.
        • Yuasa T.
        • et al.
        A phase II study of sunitinib in Japanese patients with metastatic renal cell carcinoma: insights into the treatment, efficacy and safety.
        Jpn J Clin Oncol. 2010; 40: 194
        • Yildiz I.
        • Sen F.
        • Basaran M.
        • et al.
        Response rates and adverse effects of continuous once-daily sunitinib in patients with advanced renal cell carcinoma: a single-center study in Turkey.
        Jpn J Clin Oncol. 2011; 41: 1380
        • Chu D.
        • Lacouture M.E.
        • Weiner E.
        • et al.
        Risk of hand–foot skin reaction with the multitargeted kinase inhibitor sunitinib in patients with renal cell and non-renal cell carcinoma: a meta-analysis.
        Clin Genitourin Cancer. 2009; 7: 11
        • Chu D.
        • Lacouture M.E.
        • Fillos T.
        • et al.
        Risk of hand–foot skin reaction with sorafenib: a systematic review and meta-analysis.
        Acta Oncol. 2008; 47: 176
        • Lacouture M.E.
        • Wu S.
        • Robert C.
        • et al.
        Evolving strategies for the management of hand–foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib.
        Oncologist. 2008; 13: 1001
      17. Lacouture ME. Dermatologic adverse events: the superficial side of kidney cancer therapy. In: Kidney Cancer Symposium. Chicago, 2011.

        • Manchen E.
        • Robert C.
        • Porta C.
        Management of tyrosine kinase inhibitor-induced hand–foot skin reaction: viewpoints from the medical oncologist, dermatologist, and oncology nurse.
        J Support Oncol. 2011; 9: 13
        • Robert C.
        • Soria J.C.
        • Spatz A.
        • et al.
        Cutaneous side-effects of kinase inhibitors and blocking antibodies.
        Lancet Oncol. 2005; 6: 491
        • Gomez-Fernandez C.
        • Garden B.C.
        • Wu S.
        • et al.
        The risk of skin rash and stomatitis with the mammalian target of rapamycin inhibitor temsirolimus: a systematic review of the literature and meta-analysis.
        Eur J Cancer. 2012; 48: 340
        • Dubauskas Z.
        • Kunishige J.
        • Prieto V.G.
        • et al.
        Cutaneous squamous cell carcinoma and inflammation of actinic keratoses associated with sorafenib.
        Clin Genitourin Cancer. 2009; 7: 20
        • Degen A.
        • Satzger I.
        • Voelker B.
        • et al.
        Does basal cell carcinoma belong to the spectrum of sorafenib-induced epithelial skin cancers?.
        Dermatology. 2010; 221: 193
        • Scappaticci F.A.
        • Fehrenbacher L.
        • Cartwright T.
        • et al.
        Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab.
        J Surg Oncol. 2005; 91: 173
        • Gordon C.R.
        • Rojavin Y.
        • Patel M.
        • et al.
        A review on bevacizumab and surgical wound healing: an important warning to all surgeons.
        Ann Plast Surg. 2009; 62: 707
        • Motzer R.J.
        • Mazumdar M.
        • Bacik J.
        • et al.
        Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma.
        J Clin Oncol. 1999; 17: 2530
        • Park S.
        • Lee J.
        • Park S.H.
        • et al.
        Treatment of hemodialyzed patients with sunitinib in renal cell carcinoma.
        Chemotherapy. 2010; 56: 485
        • Park C.Y.
        Successful sunitinib treatment of metastatic renal cell carcinoma in a patient with end stage renal disease on hemodialysis.
        Anticancer Drugs. 2009; 20: 848
        • Kennoki T.
        • Kondo T.
        • Kimata N.
        • et al.
        Clinical results and pharmacokinetics of sorafenib in chronic hemodialysis patients with metastatic renal cell carcinoma in a single center.
        Jpn J Clin Oncol. 2011; 41: 647
        • Masini C.
        • Sabbatini R.
        • Porta C.
        • et al.
        Use of tyrosine kinase inhibitors in patients with metastatic kidney cancer receiving haemodialysis: a retrospective Italian survey.
        BJU Int. 2012; 110: 692
        • Wu S.
        • Kim C.
        • Baer L.
        • et al.
        Bevacizumab increases risk for severe proteinuria in cancer patients.
        J Am Soc Nephrol. 2010; 21: 1381
        • Tomita Y.
        • Uemura H.
        • Fujimoto H.
        • et al.
        Key predictive factors of axitinib (AG-013736)-induced proteinuria and efficacy: a phase II study in Japanese patients with cytokine-refractory metastatic renal cell carcinoma.
        Eur J Cancer. 2011; 47: 2592
        • Yoon S.H.
        • Kim K.H.
        • Choi J.
        • et al.
        Novel sunitinib strategy in metastatic renal cell carcinoma on hemodialysis: intermittent dose of sunitinib after hemodialysis.
        Cancer Res Treat. 2010; 42: 180
        • Schmidinger M.
        • Vogl U.M.
        • Bojic M.
        • et al.
        Hypothyroidism in patients with renal cell carcinoma: blessing or curse?.
        Cancer. 2011; 117: 534
        • Wolter P.
        • Stefan C.
        • Decallonne B.
        • et al.
        The clinical implications of sunitinib-induced hypothyroidism: a prospective evaluation.
        Br J Cancer. 2008; 99: 448
        • Grossmann M.
        • Premaratne E.
        • Desai J.
        • et al.
        Thyrotoxicosis during sunitinib treatment for renal cell carcinoma.
        Clin Endocrinol (Oxf). 2008; 69: 669
        • Faris J.E.
        • Moore A.F.
        • Daniels G.H.
        Sunitinib (sutent)-induced thyrotoxicosis due to destructive thyroiditis: a case report.
        Thyroid. 2007; 17: 1147
        • Pinar D.
        • Boix E.
        • Meana J.A.
        • et al.
        Sunitinib-induced thyrotoxicosis.
        J Endocrinol Invest. 2009; 32: 941
        • Tamaskar I.
        • Bukowski R.
        • Elson P.
        • et al.
        Thyroid function test abnormalities in patients with metastatic renal cell carcinoma treated with sorafenib.
        Ann Oncol. 2008; 19: 265
        • Taha C.
        • Liu Z.
        • Jin J.
        • et al.
        Opposite translational control of GLUT1 and GLUT4 glucose transporter mRNAs in response to insulin. Role of mammalian target of rapamycin, protein kinase b, and phosphatidylinositol 3-kinase in GLUT1 mRNA translation.
        J Biol Chem. 1999; 274: 33085
        • Huffman T.A.
        • Mothe-Satney I.
        • Lawrence Jr., J.C.
        Insulin-stimulated phosphorylation of lipin mediated by the mammalian target of rapamycin.
        Proc Natl Acad Sci USA. 2002; 99: 1047
        • Appleby L.
        • Morrissey S.
        • Bellmunt J.
        • et al.
        Management of treatment-related toxicity with targeted therapies for renal cell carcinoma: evidence-based practice and best practices.
        Hematol Oncol Clin North Am. 2011; 25: 893
        • Bhojani N.
        • Jeldres C.
        • Patard J.J.
        • et al.
        Toxicities associated with the administration of sorafenib, sunitinib, and temsirolimus and their management in patients with metastatic renal cell carcinoma.
        Eur Urol. 2008; 53: 917
        • Billemont B.
        • Medioni J.
        • Taillade L.
        • et al.
        Blood glucose levels in patients with metastatic renal cell carcinoma treated with sunitinib.
        Br J Cancer. 2008; 99: 1380
        • Grundy S.M.
        • Cleeman J.I.
        • Merz C.N.
        • et al.
        Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines.
        Circulation. 2004; 110: 227
        • Motzer R.J.
        • Hudes G.R.
        • Curti B.D.
        • et al.
        Phase I/II trial of temsirolimus combined with interferon alfa for advanced renal cell carcinoma.
        J Clin Oncol. 2007; 25: 3958
        • White D.A.
        • Camus P.
        • Endo M.
        • et al.
        Noninfectious pneumonitis after everolimus therapy for advanced renal cell carcinoma.
        Am J Respir Crit Care Med. 2010; 182: 396
        • Duran I.
        • Siu L.L.
        • Oza A.M.
        • et al.
        Characterisation of the lung toxicity of the cell cycle inhibitor temsirolimus.
        Eur J Cancer. 2006; 42: 1875
        • Besse B.
        • Lasserre S.F.
        • Compton P.
        • et al.
        Bevacizumab safety in patients with central nervous system metastases.
        Clin Cancer Res. 2010; 16: 269
        • Pouessel D.
        • Culine S.
        High frequency of intracerebral hemorrhage in metastatic renal carcinoma patients with brain metastases treated with tyrosine kinase inhibitors targeting the vascular endothelial growth factor receptor.
        Eur Urol. 2008; 53: 376
        • Gore M.E.
        • Hariharan S.
        • Porta C.
        • et al.
        Sunitinib in metastatic renal cell carcinoma patients with brain metastases.
        Cancer. 2011; 117: 501
        • Grunwald V.
        • Seidel C.
        • Fenner M.
        • et al.
        Treatment of everolimus-resistant metastatic renal cell carcinoma with VEGF-targeted therapies.
        Br J Cancer. 2011; 105: 1635
        • Chen A.
        • Agarwal N.
        Reversible posterior leucoencephalopathy syndrome associated with sunitinib.
        Intern Med J. 2009; 39: 341
        • Padhy B.M.
        • Shanmugam S.P.
        • Gupta Y.K.
        • et al.
        Reversible posterior leucoencephalopathy syndrome in an elderly male on sunitinib therapy.
        Br J Clin Pharmacol. 2011; 71: 777
        • Martin G.
        • Bellido L.
        • Cruz J.J.
        Reversible posterior leukoencephalopathy syndrome induced by sunitinib.
        J Clin Oncol. 2007; 25: 3559
        • Cumurciuc R.
        • Martinez-Almoyna L.
        • Henry C.
        • et al.
        Posterior reversible encephalopathy syndrome during sunitinib therapy.
        Rev Neurol (Paris). 2008; 164: 605
        • Hinchey J.
        • Chaves C.
        • Appignani B.
        • et al.
        A reversible posterior leukoencephalopathy syndrome.
        N Engl J Med. 1996; 334: 494
        • Mulherin B.
        • Loconte N.K.
        • Holen K.D.
        Guillain–Barre syndrome after treatment with sunitinib malate?.
        Oncology (Williston Park). 2008; 22: 66
        • Guarneri V.
        • Miles D.
        • Robert N.
        • et al.
        Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer.
        Breast Cancer Res Treat. 2010; 122: 181
        • Christodoulou C.
        • Pervena A.
        • Klouvas G.
        • et al.
        Combination of bisphosphonates and antiangiogenic factors induces osteonecrosis of the jaw more frequently than bisphosphonates alone.
        Oncology. 2009; 76: 209
        • Hoefert S.
        • Eufinger H.
        Sunitinib may raise the risk of bisphosphonate-related osteonecrosis of the jaw: presentation of three cases.
        Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2010; 110: 463
        • Fleissig Y.
        • Regev E.
        • Lehman H.
        Sunitinib related osteonecrosis of jaw: a case report.
        Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2012;
        • Koch F.P.
        • Walter C.
        • Hansen T.
        • et al.
        Osteonecrosis of the jaw related to sunitinib.
        Oral Maxillofac Surg. 2011; 15: 63
        • Wilson K.G.
        • Chochinov H.M.
        • Skirko M.G.
        • et al.
        Depression and anxiety disorders in palliative cancer care.
        J Pain Symptom Manage. 2007; 33: 118
        • Beaumont J.L.
        • Butt Z.
        • Baladi J.
        • et al.
        Patient-reported outcomes in a phase iii study of everolimus versus placebo in patients with metastatic carcinoma of the kidney that has progressed on vascular endothelial growth factor receptor tyrosine kinase inhibitor therapy.
        Oncologist. 2011; 16: 632
        • Bukowski R.
        • Cella D.
        • Gondek K.
        • et al.
        Effects of sorafenib on symptoms and quality of life: results from a large randomized placebo-controlled study in renal cancer.
        Am J Clin Oncol. 2007; 30: 220
        • Cella D.
        • Li J.Z.
        • Cappelleri J.C.
        • et al.
        Quality of life in patients with metastatic renal cell carcinoma treated with sunitinib or interferon alfa: results from a phase III randomized trial.
        J Clin Oncol. 2008; 26: 3763
        • Cella D.
        • Pickard A.S.
        • Duh M.S.
        • et al.
        Health-related quality of life in patients with advanced renal cell carcinoma receiving pazopanib or placebo in a randomised phase III trial.
        Eur J Cancer. 2012; 48: 311
        • Yang S.
        • de Souza P.
        • Alemao E.
        • et al.
        Quality of life in patients with advanced renal cell carcinoma treated with temsirolimus or interferon-alpha.
        Br J Cancer. 2010; 102: 1456
      18. Escudier, B, Porta, C, Bono, P, et al. Patient preference between pazopanib (Paz) and sunitinib (Sun): results of a randomized double-blind, placebo-controlled, cross-over study in patients with metastatic renal cell carcinoma (mRCC)—PISCES study, NCT 01064310. In: American Society of Clinical Oncology meeting. Chicago, IL; 2012.

      19. Drug interactions. Indiana University School of Medicine; 2009.